With the world’s attention on new and re-emerging outbreaks of COVID-19, advocates are working towards policies that ensure care for overshadowed patient groups.
As the COVID-19 crisis grows, policymakers may be overlooking a vulnerable population: patients living with rheumatic and musculoskeletal diseases like rheumatoid arthritis.
A new report spotlights the need for patient-centred neurological care across the globe.
This month’s JAMA Cardiology features an international call to action from the global community impacted by familial hypercholesterolemia, or FH.
Earlier, more aggressive cholesterol management could reap important cardiovascular benefits, a recent study reports.
Not all patients have enough information to protect themselves from preventable heart attacks and strokes, a newly released questionnaire of European patients confirms.
Patient advocacy organisations across Europe are banding together to improve cardiovascular health.
Development of biosimilars has expanded patients’ treatment options by offering innovative medicine at lower costs than traditional biologics. So why are some nations slow to adopt biosimilars?
New medical guidelines often come with an intrinsic irony.
The European Society of Cardiology has released new guidelines recommending that patients lower their LDL cholesterol to reduce their risk of cardiovascular disease. But the guidelines don’t just reinforce an important truth. They make it actionable for patients.